Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q1FY24 of ₹395.00 Crores up from ₹346.00 Crore year on year, a rise of 14.16%.
Total Expenses for Q1FY24 of ₹280.00 Crores up from ₹255.00 Crores year on year, a rise of 9.8%.
Consolidated Net Profit of ₹104.00 Crores up 20.93% from ₹86.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹13.62, up 21.50% from ₹11.21 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.